The Journal of Korean Medicine (대한한의학회지)

The Society of Korean Medicine (대한한의학회)
권호 표지

The Concurrent Use of Rhus verniciflua Stokes as Complementary Therapy with Second or More Line Regimens on Advanced Non-small-cell Lung Cancer: Case Series

  • Lee, Sang-Hun (Department of Internal Medicine, M.u Integrative Cancer Center, East-West Neo Medical Center, College of Oriental Medicine, Kyunghee University) ;
  • Kim, Kyung-Suk (Department of Internal Medicine, M.u Integrative Cancer Center, East-West Neo Medical Center, College of Oriental Medicine, Kyunghee University) ;
  • Choi, Won-Cheol (Department of Clinical Oncology, M.u Integrative Cancer Center, East-West Neo Medical Center, College of Oriental Medicine, Kyunghee University) ;
  • Yoon, Seong-Woo (Department of Internal Medicine, M.u Integrative Cancer Center, East-West Neo Medical Center, College of Oriental Medicine, Kyunghee University)
  • Published : 2009.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Rhus verniciflua Stokes (RVS) has anticancer effect confirmed by preclinical studies and historical records. We thus tried to evaluate retrospectively the effect of RVS as a complementary medicine for patients with advanced non-small-cell lung cancer (NSCLC) showing refractory to conventional chemotherapy. Patients and Methods: From June 1, 2006 to June 30, 2007, patients with advanced NSCLC who received both the standardized RVS extract and a standard course of second or more line therapy such as pemetrexed ($Alimta^{(R)}$), erlotinib ($Tarceva^{(R)}$), and gefitinib ($Iressa^{(R)}$) were checked. A total of 13 patients were eligible for the final analysis after fulfilling inclusion/exclusion criteria. Time to progression (TTP) of these patients treated with the standardized RVS extract was checked in the aftercare period. Results: Patients received RVS treatment for a median period of 296 (range 84-698) days. The median TTP was 220.5 (range 36-489) days, and three patients (23.1%) had TTP values of 15 more months. No significant side effects from RVS treatment have been observed. Conclusion: The standardized RVS extract might have synergetic effects by assisting apoptosis in advanced NSCLC with concurrent standard therapy agents, since it prolonged TTP without significant adverse effects. This study suggests that the standardized RVS extract is beneficial to patients with chemotherapy-refractory NSCLC. Further clinical trials and preclinical studies are necessary to determine the efficacy and safety of the standardized RVS extract in NSCLC.

Keywords

References

  1. Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003; 123 (Suppl 1):226-43. https://doi.org/10.1378/chest.123.1_suppl.226S
  2. Johnson DH. Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2006; 12:S4451-7. https://doi.org/10.1158/1078-0432.CCR-06-0095
  3. Jeong JS, Park JW, Yoon SW, Choi WC. Carcinostatic effect of allergen removed Rhus verniciflua Stokes-based traditional Korean medicine on a patient with lung adenocarcinoma; single case report. OPEM. 2008; 5:573-8.
  4. Jang HS, Kook SH, Son YO, Kim JG, Jeon YM, Jang YS, et al. Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells. Biochem. Biophys Acta. 2005; 1726(3):309-16. https://doi.org/10.1016/j.bbagen.2005.08.010
  5. Son YO, Lee KY, Lee JC, Jang HS, Kim JG, Jeon YM, et al. Selective antiproliferative and apoptotic effects of flavonoids purified from Rhus verniciflua Stokes on normal versus transformed hepatic cell lines. Toxicol Let. 2005; 155(1):115-25. https://doi.org/10.1016/j.toxlet.2004.09.003
  6. Choi WC, Lee JH, Lee EO. Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extract. Korean J Oriental Physiology & Pathology. 2006; 20:825-9.
  7. Lee JH, Lee HJ, Lee HJ, Choi WC, Yoon SW, Ko SG, et al. Rhus verniciflua Stokes prevents cisplatin-induced cytotoxicity and reactive oxygen species production in MDCK-I renal cells and intact mice. Phytomedicine. 2009; 16(2-3):188-97. https://doi.org/10.1016/j.phymed.2008.10.009
  8. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest. 2005; 128(6):3975-84. https://doi.org/10.1378/chest.128.6.3975
  9. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 2001; 8:3-9. https://doi.org/10.1677/erc.0.0080003
  10. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res. 2004; 10:S4276-80. https://doi.org/10.1158/1078-0432.CCR-040010
  11. Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist. 2005; 10(6):363-8. https://doi.org/10.1634/theoncologist.10-6-363
  12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. https://doi.org/10.1056/NEJMoa050753
  13. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008; 13(Suppl 2):19-21. https://doi.org/10.1634/theoncologist.13-S2-19
  14. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366(9496):1527-37. https://doi.org/10.1016/S0140-6736(05)67625-8
  15. Lovell CR. Poison oak. In: Plants and the Skin. Blackwell Scientific Publications: Oxford; 1993:106-10.
  16. Kook SH, Son YO, Chung SW, Lee SA, Kim JG, Jeon YM, et al. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis. 2007; 12(7):1289-98. https://doi.org/10.1007/s10495-007-0056-x
  17. Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, et al. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Let. 2008; 265(2):197-205. https://doi.org/10.1016/j.canlet.2008.02.039